This article was originally published in The Gray Sheet
Firm's IsoStar I-125 brachytherapy seeds will be launched by Imagyn Medical Technologies in the fourth quarter of 1998. Under a deal inked by the firms in January, Imagyn has exclusive worldwide marketing rights to the 510(k)-cleared radioactive seeds used in the treatment of tumors ("The Gray Sheet" Jan. 26, In Brief)
You may also be interested in...
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.